Business Context and Reporting Period
Company: Minerva Neurosciences, Inc. (Ticker: NERV)
Filing Type: Form 8-K (Current Report)
Date of Report: January 10, 2025
Subject: Item 8.01 Other Events regarding Nasdaq listing compliance status.
Key Financial Metrics
This filing does not contain specific financial performance data such as revenue, profit, cash flow, margins, or debt levels. The document focuses exclusively on regulatory compliance status with The Nasdaq Stock Market LLC.
Material Changes and Regulatory Status
- Previous Deficiency: On April 10, 2024, the Company received notice of non-compliance with Nasdaq Listing Rule 5550(b)(2) (Market Value of Listed Securities or "MVLS Rule") due to a market value below $35 million for 31 consecutive business days.
- Current Status: Following a hearing on December 10, 2024, the Nasdaq Hearings Panel granted the Company's request for continued listing on January 10, 2025.
- Conditions for Continued Listing: The grant is conditional upon the Company meeting specific requirements by March 31, 2025.
Outlook, Requirements, and Risks
The Company must satisfy the following conditions by March 31, 2025 to maintain its listing:
- Equity Compliance: File a public disclosure describing transactions undertaken to achieve compliance with Nasdaq Listing Rule 5550(b)(1) (the "Equity Rule"), which requires minimum stockholders' equity of $2.5 million, and provide an indication of equity following those transactions.
- Income Projections: Provide the Panel with income projections for the next 12 months, including clearly stated underlying assumptions, and evidence of compliance with all applicable listing criteria.
Risks: The filing explicitly states there is no assurance the Company will regain compliance with the Equity Rule or MVLS Rule, maintain other listing standards, or continue its listing on Nasdaq.
Investor Verification Checklist
- Verify the Company's current stockholders' equity to assess proximity to the $2.5 million threshold.
- Monitor upcoming filings for the required public disclosure of transactions intended to restore equity compliance.
- Review the income projections for the next 12 months once filed to evaluate the Company's path to profitability.
- Track the stock price and market capitalization to ensure the MVLS Rule ($35 million) is not breached again.